About Enhancer
| Enhancer ID: | E_01_0799 |
| Species: | human |
| Position : | chr7:27195996-27197996   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Renal cell carcinoma (rcc) |
| Pubmed ID: | 30021349 |
| Enhancer experiment: | RT qPCR, chromatin immunoprecipitation (chip) analysis, Western blot, statistical analysis, immunoblotting analysis |
| Enhancer experiment description: | Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression. |
About Target gene
| Target gene : | HOTTIP,LATS2 |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression.;Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression.;Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression. |
About TF
| TF name : | EZH2(ENX-1,ENX1b,KMT6,KMT6A,WVS,WVS2,EZH2) |
| TF experiment: | RT-qPCR,Chromatin immunoprecipitation (ChIP) analysi,western blot,????,Immunoblotting analysis |
| TF experiment description: | Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression.;Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression.;Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression. |
About Function
| Enhancer function : | Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
Specifically, HOTTIP is upregulated and exerts oncogenic properties in some cancers. The mechanistic investigations showed that HOTTIP could bind to enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1), thereby repressing LATS2 expression. |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene